… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” Business Operations and … ® EONs are designed to recruit an endogenously expressed RNAediting system called ADAR, which can direct the change …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board. Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the Company’s …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … Annual Conference A presentation titled “Therapeutic RNAediting by Axiomer ® editing oligonucleotides” by Janne …